Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

D. Demetri, George; von Mehren, Margaret; D. Blanke, Charles; D. Van den Abbeele, Annick; Eisenberg, Burton; Roberts‎, Peter; C. Heinrich, Michael; A. Tuveson, David; Singer, Samuel; J. Janicek, Milos; A. Fletcher, Jonathan; G. Silverman, Stuart; Silberman, Sandra; Capdeville, Renaud; Kiese, Beate; Peng, Bin; Dimitrijević, Saša; Druker, Brian; L. Corless, Christopher; D.�M. Fletcher, Christopher; Joensuu, Heikki

doi:10.1056/nejmoa020461

Public

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

Published in New England Journal of Medicine • Aug 15, 2002

Authors:

George D. Demetri

Margaret von Mehren

Charles D. Blanke

Abstract

BACKGROUND: Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors...

Subject

Medicine

Imatinib

Imatinib mesylate

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!